Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Forma Therapeutics Holdings, Inc.FMTX · Entity 123059 | SVP, Chief Scientific Officer | February 28, 2022 | March 02, 2022 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | January 26, 2019 | January 29, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Forma Therapeutics Holdings, Inc.
Report date February 28, 2022 · Filed March 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,469 |
Reported balance
After 2022-02-28 transaction · row 1
1 source rowRow 1 · 2022-02-28 · Grant · Acquired 25,000 · Balance 41,469 F1: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.86 · Expires 2032-02-27 | Direct | 37,500 |
Reported balance
After 2022-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-28 · Grant · Acquired 37,500 · Balance 37,500 F2: 25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.
F2: 25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter.
Seres Therapeutics, Inc.
Report date January 26, 2019 · Filed January 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 147,435 |
Reported balance
After 2019-01-26 transaction · row 1
1 source rowRow 1 · 2019-01-26 · Exercise / conversion · Acquired 7,500 · Balance 147,435 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
| RESTRICTED STOCK UNITSSEC Table II · derivative / convertible security | Direct | 12,500 |
Reported balance
After 2019-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-26 · Exercise / conversion · Disposed 7,500 · Balance 12,500 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2022 Filed Mar 2, 2022 17:14 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $9.86 | $0.00 |
DisclosureSEC source: 0000899243-22-008644 · doc4.xml · derivative · entry 2 COOK DAVID N · CIK 0001233684 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2032-02-27 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 28, 2023, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 17:14 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-008644 · doc4.xml · nonDerivative · entry 1 COOK DAVID N · CIK 0001233684 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,469 F1 · shares: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 17:09 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | SaleCommon Stock | 3,531 | $9.78 | $34,524.35 |
DisclosureSEC source: 0000899243-22-007924 · doc4.xml · nonDerivative · entry 1 COOK DAVID N · CIK 0001233684 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,469 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.61 to $10.005. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:29 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantStock Option (Right to Buy) · Derivative | 43,550 | $0.00 Strike: $38.61 | $0.00 |
DisclosureSEC source: 0000899243-21-009155 · doc4.xml · derivative · entry 3 COOK DAVID N · CIK 0001233684 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,550 Underlying: Common Stock · 43,550 shares Expires 2031-02-25 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 22, 2022, and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:29 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantCommon Stock | 5,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009155 · doc4.xml · nonDerivative · entry 2 COOK DAVID N · CIK 0001233684 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 20:29 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantCommon Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009155 · doc4.xml · nonDerivative · entry 1 COOK DAVID N · CIK 0001233684 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 F1 · shares: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 19:41 UTC | Forma Therapeutics Holdings, Inc. FMTX · Entity 123059 | GrantStock Option (Right to Buy) · Derivative | 23,378 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017449 · doc4.xml · derivative · entry 1 COOK DAVID N · CIK 0001233684 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,378 shares Expires 2030-06-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on June 18, 2021 and the remainder of the shares vest in equal monthly installments for a period of 36 months thereafter. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 18:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-002136 · doc4.xml · derivative · entry 2 COOK DAVID N · CIK 0001233684 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020. F2 · derivative.expiration_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 18:51 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-002136 · doc4.xml · nonDerivative · entry 1 COOK DAVID N · CIK 0001233684 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 20:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 75,000 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0000899243-18-002327 · doc4.xml · derivative · entry 4 COOK DAVID N · CIK 0001233684 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: COMMON STOCK · 75,000 shares Expires 2028-01-29 F3 · derivative.exercise_date: The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 20:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRESTRICTED STOCK UNITS · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002327 · doc4.xml · derivative · entry 3 COOK DAVID N · CIK 0001233684 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: COMMON STOCK · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. F2 · derivative.expiration_date: These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 20:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCOMMON STOCK | 1,738 | $11.02 | $19,152.76 |
DisclosureSEC source: 0000899243-18-002327 · doc4.xml · nonDerivative · entry 2 COOK DAVID N · CIK 0001233684 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,935 Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 20:58 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCOMMON STOCK | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002327 · doc4.xml · nonDerivative · entry 1 COOK DAVID N · CIK 0001233684 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 17:50 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-002119 · doc4.xml · derivative · entry 2 COOK DAVID N · CIK 0001233684 · Chief Scientific Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020. F3 · derivative.expiration_date: These restricted stock units vest as to 20% on January 26, 2018, 30% on January 26, 2019 and 50% on January 26, 2020. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 17:50 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0000899243-17-002119 · doc4.xml · derivative · entry 1 COOK DAVID N · CIK 0001233684 · Chief Scientific Officer & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 26, 2018. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.